Comparative Pharmacology
Head-to-head clinical analysis: MINASTRIN 24 FE versus ZOVIA 1 50E 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MINASTRIN 24 FE versus ZOVIA 1 50E 21.
MINASTRIN 24 FE vs ZOVIA 1/50E-21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an estrogen (ethinyl estradiol) and a progestin (norethindrone acetate) that inhibits gonadotropin release from the pituitary, suppressing ovulation, thickening cervical mucus, and altering endometrial receptivity.
Combination estrogen-progestin contraceptive: Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; Norethindrone induces cervical mucus thickening and endometrial thinning, impeding sperm penetration and implantation.
One tablet orally once daily for 24 weeks, followed by 4 placebo tablets. Each tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol for 21 days, then 1 mg norethindrone acetate and 0.75 mg ferrous fumarate for 7 days.
One tablet orally once daily for 21 consecutive days, followed by 7 placebo tablets for 28-day cycle.
None Documented
None Documented
Norethindrone: 7-8 hours; ethinyl estradiol: 13-27 hours. Clinical context: Steady-state achieved within 5-10 days; half-life supports once-daily dosing.
Terminal elimination half-life: 13±3 hours (range 10-20 h) for the progestin component; clinical context: steady-state achieved within 5 days, with minimal accumulation.
Urine (primarily as glucuronide conjugates; ethinyl estradiol and norethindrone metabolites) and feces. Approximately 40% of norethindrone metabolites are excreted in urine and 60% in feces. Ethinyl estradiol is excreted as glucuronide and sulfate conjugates in urine (40%) and feces (60%).
Renal: ~50% (metabolites); Fecal: ~30% (metabolites); Biliary: minor; Unchanged drug: <1% renal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive